Table 1.

Clinicopathologic characteristics of HCC patients in cohorts for IHC, real-time PCR, or western blot

	Cohort 1 (n = 80, for IHC)	Cohort 2 (n = 64, for real-time PCR)	Cohort 3 (n = 52, for western blot)
Characteristics	No. of patients (%)	No. of patients (%)	No. of patients (%)
Gender
Male	72 (90.0%)	54 (84.4%)	36 (69.2%)
Female	8 (10.0%)	10 (15.6%)	16 (30.8%)
Age
<54	38 (47.5%)	28 (43.8%)	26 (50.0%)
≥54	42 (52.5%)	36 (56.2%)	26 (50.0%)
HBV infection
Yes	14 (17.5%)	20 (31.3%)	20 (38.5%)
No	66 (82.5%)	44 (68.7%)	32 (61.5%)
Liver cirrhosis history
Yes	75 (93.8%)	48 (75.0%)	39 (75.0%)
No	5 (6.2%)	16 (25.0%)	13 (25.0%)
Tumor size
<5 cm	39 (48.8%)	34 (53.1%)	35 (67.3%)
≥5 cm	41 (51.2%)	30 (46.9%)	17 (32.7%)
TNM stage
I	36 (45.0%)	31 (48.4%)	33 (63.5%)
II	3 (3.8%)	3 (4.7%)	2 (3.8%)
III	37 (46.2%)	21 (32.8%)	11 (21.2%)
IV	4 (5.0%)	9 (14.1%)	6 (11.5%)
BCLC stage
0	2 (2.5%)	14 (21.9%)	1 (1.9%)
A	39 (48.8%)	19 (29.7%)	29 (55.8%)
B	13 (16.3%)	8 (12.5%)	12 (23.1%)
C	25 (31.2%)	23 (35.9%)	8 (15.4%)
D	1 (1.2%)	0 (0.0%)	2 (3.8%)